Comparison of Empagliflozin-Linagliptin with Empagliflozin- Metformin Combination Therapy in Assessing Cardiovascular Profile and Anemia in Type 2 Diabetic Patients
Abstract
Objective: This study aimed to compare the effects of empagliflozin-metformin versus empagliflozin- linagliptin combination
therapy on cardiovascular parameters and anemia in patients with type 2 diabetes mellitus (T2DM).
Study Design and setting: An analytical study was conducted over 12 weeks at National Medical Centre Hospital, Karachi.
Methodology: T2DM patients were randomly assigned to either the Empagliflozin 12. 5 mg with Metformin 500mg or
Empagliflozin 10mg with Linagliptin 5mg. Clinical assessments were conducted at baseline Week 0, 4, and 12, focusing
on C-reactive protein levels, blood pressure, temperature, heart rate, respiratory rate, ECG findings, hemoglobin levels,
BMI, and glycated hemoglobin (HbA1c) and cardiac examination was performed in all visits. Descriptive statistics were
used to compare outcomes between the groups.
Results: The comparative analysis of empagliflozin–metformin (EM) and empagliflozin–linagliptin (EL) regimens
demonstrated notable differences in outcomes. HbA1c decreased significantly in both groups, but the EL group showed a
greater reduction by week 12 (p = 0.021, OR = 1.65, 95% CI: 1.05–2.58). BMI declined in both arms, but intergroup difference
was not statistically significant (p = 0.078). CRP levels dropped more in the EL group, reaching statistical significance (p
= 0.037, OR = 1.43, 95% CI: 1.01–2.11). Cardiovascular parameters, including systolic BP (p = 0.116) and diastolic BP
(p = 0.098), remained stable, showing no…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.